Key Developments For Home Diagnostics, Inc.
Home Diagnostics, Inc. (HDIX.O) (Nasdaq)
Home Diagnostics, Inc Lowers FY 2009 Guidance
Home Diagnostics, Inc adjusted fiscal 2009 guidance and expects total revenue to be in the range of $126-$127 million and diluted earnings per share (EPS) to be in the range of $0.30-$0.32 from the previous estimate of $129-$131 million and diluted earnings per share in the range of $0.36-$0.38. According to Reuters Estimates, analysts were expecting the Company to report revenues of $130 million and EPS of $0.37 for the same period.
Home Diagnostics, Inc Announces Accuracy Of Store Brand TRUEresult Blood Glucose Monitoring System In Comparison To Name Brand Systems
Home Diagnostics, Inc announced that a new study has shown that its TRUEresult store brand blood glucose monitoring system is comparable to the performance of more expensive name brand systems. The comparative study, titled Accuracy Study of Blood Glucose Monitoring Systems, evaluated the performance of four commercially available blood glucose monitors, including LifeScan`s OneTouch Ultra 2, Bayer`s Ascensia Contour and Abbott`s FreeStyle Freedom Lite, and found that TRUEresult, Home Diagnostics` store-branded meter, yielded accurate results comparable to those obtained by the more expensive name brand products. The study of 100 subjects with Type 1 and Type 2 diabetes leveraged stringent quality standards in evaluating meter performance. System accuracy was compared to the Yellow Springs Instrument (YSI) reference laboratory method for glucose readings. In addition, all systems were evaluated using the International Standard Organization in ISO 15197: 2003 criteria for evaluating the performance of blood glucose monitoring devices, the most rigorous performance standard in the blood glucose monitoring industry. Study results found that the TRUEresult system performance exceeded the minimum performance criteria outlined in the ISO protocol with 199 out of 200 (99.5 percent) results within the ISO stated accuracy limits.
Home Diagnostics, Inc Lowers FY 2009 Revenue Guidance; Lowers Upper End Of Prior FY 2009 EPS Guidance To A Range In Line With Analysts' Estimates; Comments On H2 2009 Guidance
Home Diagnostics, Inc announced that it is updating its fiscal 2009 guidance of revenue to now be in the range of $129-$131 million and diluted earnings per share (EPS) to be in the range of $0.36 to $0.38 from the previous estimate of $130-$133 million and EPS in the range of $0.36 to $0.40. The Company anticipates that second half of 2009 revenue and earnings will be more heavily weighted towards the fourth quarter due to the timing of purchases in the distribution channel and the ramp up of new product launches. According to Reuters Estimates, analysts are expecting the Company to report revenue of $130 million and EPS of $0.38 for fiscal 2009; revenue of $38 million and EPS of $0.21 for the third quarter of 2009; revenue of $34 million and EPS of $0.17 for the fourth quarter of 2009.
Home Diagnostics, Inc Receives CE Mark Approval For TRUEtest Product Platform; Added To Russell 3000, Russell 2000 and Russell Global Indexes
Home Diagnostics, Inc announced that it received CE Mark approval for the TRUEtest product platform. The Company also announced that it has been added to Russell 3000, Russell 2000 and Russell Global Indexes.
Home Diagnostics, Inc Issues FY 2009 Guidance In Line With Analysts' Estimates
Home Diagnostics, Inc announced that for fiscal 2009 it expects total revenue to be in the range of $130 million to $133 million, representing annual growth of 5% to 8%. The Company anticipates 2009 diluted earnings per share to be in the range of $0.36 to $0.40. According to Reuters Estimates, analysts are expecting the Company to report revenue of $130 million and EPS of $0.40 for fiscal 2009.
